The effect of beraprost sodium on the surrogate markers of atherosclerosis in type 2 diabetes mellitus

The effect of beraprost sodium on the surrogate markers of atherosclerosis in type 2 diabetes mellitus - The effect of beraprost sodium on the surrogate markers of atherosclerosis in type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011137

Enrollment

Registered

2013-07-06

Start date

2013-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Duration 6 months Subject type 2 diabetes mellitus Drug therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who has stable glycemic control (HbA1c less than 8.4% (NGSP)) Patient who has stable blood pressure control Patient whose ABI is between 0.9 and 1.0 and who is diagnosed as ASO clinically

Exclusion criteria

Exclusion criteria: Patient whom beraprost sodium is contraindicated for Patient who takes vasodilator (nitrates) Patinet who has been started anitiplatelet drugs and/or drugs for dyslipidemia within 3 months before starting beraprost sodium Patinet who have been changed drugs for diabetes mellitus within 3 months before starting beraprost sodium Patient whose ABI is less than 0.9 Patinet who take glucocorticoids and NSAID (except aspirin) Patient who has the impairment of renal function (Cr more than 2 mg/dl) Patient who is unsuitable for this study (judged by a doctor)

Design outcomes

Primary

Measure	Time frame
Atherosclerosis, glucose metabolism, diabetic nephropathy, QOL	—

Countries

Japan

Contacts

Public ContactMichio Otsuki

Osaka University Graduate School of Medicine Department of Metabolic Medicine

otsuki@endmet.med.osaka-u.ac.jp06-6879-3732

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026